X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Zevtera (ceftobiprole medocaril sodium) is approved for adult patients with S. aureus bloodstream infections, and adult patients with acute bacterial skin and skin structure infections and for adult and pediatric patients with community-acquired bacterial pneumonia.
Lead Product(s): Ceftobiprole Medocaril
Therapeutic Area: Infections and Infectious Diseases Product Name: Zevtera
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2024
Details:
Zevtera (ceftobiprole medocaril sodium) is a cephalosporin antibiotic for intravenous administration, which is investigated for Staphylococcus aureus bacteremia (SAB), including right-sided infective endocarditis, acute bacterial skin and skin structure infections.
Lead Product(s): Ceftobiprole Medocaril
Therapeutic Area: Infections and Infectious Diseases Product Name: Zevtera
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2023
Details:
Zevtera (ceftobiprole medocaril sodium) is a cephalosporin antibiotic for intravenous administration, with rapid bactericidal activity against a wide range of gram-positive and gram-negative bacteria.
Lead Product(s): Ceftobiprole Medocaril
Therapeutic Area: Infections and Infectious Diseases Product Name: Zevtera
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2023
Details:
Zevtera (ceftobiprole medocaril sodium) is a cephalosporin antibiotic for intravenous administration, with rapid bactericidal activity against a wide range of gram-positive and gram-negative bacteria.
Lead Product(s): Ceftobiprole Medocaril
Therapeutic Area: Infections and Infectious Diseases Product Name: Zevtera
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Details:
Zevtera (ceftobiprole medocaril), the prodrug of the active moiety ceftobiprole, is a cephalosporin antibiotic for intravenous administration, with rapid bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria.
Lead Product(s): Ceftobiprole Medocaril
Therapeutic Area: Infections and Infectious Diseases Product Name: Zevtera
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
Details:
Zevtera (ceftobiprole medocaril), the prodrug of the active moiety ceftobiprole, is a cephalosporin antibiotic. The positive results underline the potent activity of ceftobiprole for treating serious bacterial infections.
Lead Product(s): Ceftobiprole Medocaril
Therapeutic Area: Infections and Infectious Diseases Product Name: Zevtera
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2022
Details:
Zevtera (ceftobiprole) was well tolerated and the observed safety profile was consistent with previous phase 3 studies and the post-marketing experience with ceftobiprole. In the ERADICATE study the overall rate of adverse events was similar between the two treatment groups.
Lead Product(s): Ceftobiprole Medocaril
Therapeutic Area: Infections and Infectious Diseases Product Name: Zevtera
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2022
Details:
BARDA funding has supported the successful completion of Basilea Pharmaceutica, skin infections phase 3 TARGET study and supporting second study, the ERADICATE study, is evaluating the use of ceftobiprole for the treatment of patients with Staphylococcus aureus bacteremia.
Lead Product(s): Ceftobiprole Medocaril
Therapeutic Area: Infections and Infectious Diseases Product Name: Zevtera
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: BARDA
Deal Size: $134.2 million Upfront Cash: Undisclosed
Deal Type: Funding August 16, 2021
Details:
Ceftobiprole medocaril, Zevtera, is a novel cephalosporin antibiotic indicated for the treatment of serious bacterial infections in hospitalised patients.
Lead Product(s): Ceftobiprole Medocaril
Therapeutic Area: Infections and Infectious Diseases Product Name: Zevtera
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Nordic Capital
Deal Size: $846.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition June 01, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
